Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 ... The Herald | HeraldOnline.com A second study in 40 patients with HR CLL treated with the combination of ibrutinib and rituximab therapy reported an ORR of 83 percent, with 38 of the 40 patients continuing on therapy without disease progression. Patients with HR disease have ... New Investigational Agent Targets Gene Signaling Pathways to Improve ... |
